

# Investigation of rheumatoid arthritis susceptibility genes identifies association of *AFF3* and *CD226* variants with response to anti-tumour necrosis factor treatment

Rachael J L Tan,<sup>1</sup> Laura J Gibbons,<sup>1</sup> Catherine Potter,<sup>2</sup> Kimme L Hyrich,<sup>1</sup> Ann W Morgan,<sup>3</sup> Anthony G Wilson,<sup>4</sup> John D Isaacs,<sup>2</sup> BRAGGSS, Anne Barton<sup>1</sup>

► Additional data are published online only. To view these files please visit the journal online (<http://ard.bmj.com>).

<sup>1</sup>Arthritis Research Campaign Epidemiology Unit, University of Manchester, Manchester, UK; <sup>2</sup>Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, UK; <sup>3</sup>NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, UK; <sup>4</sup>University of Sheffield, Sheffield, UK

## Correspondence to

Dr Anne Barton, Arthritis Research Campaign Epidemiology Unit, Stopford Building, Oxford Road, University of Manchester, Manchester M13 9PT, UK; [anne.barton@manchester.ac.uk](mailto:anne.barton@manchester.ac.uk)

RJLT and LJG contributed equally to this work.

Accepted 3 December 2009

## ABSTRACT

**Background** Anti-tumour necrosis factor (anti-TNF) therapy has proved to be highly successful in treating rheumatoid arthritis (RA), although 30–40% of patients have little or no response. The authors hypothesise that this may be genetically determined. In other complex diseases, susceptibility genes have been shown to influence treatment response. The aim of the current study was to investigate the association of markers within confirmed RA susceptibility loci with the response to anti-TNF treatment.

**Methods** Eighteen single nucleotide polymorphisms (SNPs) mapping to 11 genetic loci were genotyped in 1012 patients with RA receiving treatment with etanercept, infliximab or adalimumab. Multivariate linear regression analyses were performed using the absolute change in 28 joint count disease activity score (DAS28) between baseline and 6-month follow-up as the outcome variable, adjusting for confounders. *p* Values <0.05 were considered statistically significant and associated markers were genotyped in an additional 322 samples. Analysis was performed in the combined cohort of 1334 subjects with RA treated with anti-TNF.

**Results** In the combined analysis, SNPs mapping to *AFF3* and *CD226* had a statistically significant association with the response to anti-TNF treatment under an additive model. The G allele at rs10865035, mapping to *AFF3*, was associated with an improved response to anti-TNF treatment (coefficient  $-0.14$  (95% CI  $-0.25$  to  $-0.03$ ),  $p=0.015$ ). At the *CD226* SNP rs763361, the C allele conferred reduced response to treatment (coefficient  $0.11$  (95% CI  $0.00$  to  $0.22$ ),  $p=0.048$ ).

**Conclusion** These results suggest that *AFF3* and *CD226*, two confirmed RA susceptibility genes, have an additional role in influencing the response to anti-TNF treatment.

## INTRODUCTION

Rheumatoid arthritis (RA) is a chronic potentially disabling disease caused by autoimmune destruction of the synovial joints which affects approximately 1% of the Caucasian population.<sup>1</sup> The introduction of anti-tumour necrosis factor (anti-TNF) biological therapies has dramatically altered the treatment of RA as they show good efficacy in patients resistant to disease-modifying anti-rheumatic drugs (DMARDs) and superior efficacy

in the suppression of erosive damage compared with standard DMARDs.<sup>2</sup> However, there remains a significant non-response rate (in the region of 30–40%). The reasons for this remain largely unknown.<sup>3</sup> Furthermore, anti-TNF therapy is associated with expensive annual treatment costs, leading to restrictions in the numbers of patients who may be prescribed these drugs. The identification of predictors of treatment response could potentially reduce the number of non-responding patients, improving the cost-effectiveness of anti-TNF therapies.

Several clinical predictors of response have been determined, including the level of disability at the onset of treatment as measured by the Health Assessment Questionnaire (HAQ) (patients with higher levels of disability at the outset of therapy respond less well); concurrent therapy with DMARDs (co-administration of DMARDs improves response); and the presence of autoantibodies (presence of rheumatoid factor or anticyclic citrullinated peptide antibodies is associated with a poorer response).<sup>4,5</sup> However, even when these factors were combined, they accounted for less than 20% of the variance in response to anti-TNF agents in one study.<sup>5</sup>

In other complex diseases, polymorphisms in susceptibility genes have been shown to be associated with treatment response. For example, two variants in the established type 2 diabetes (T2D) susceptibility gene *TCF7L2* have been shown to influence the response to treatment with sulfonylurea drugs.<sup>6</sup> In the current study we hypothesised that polymorphisms known to have a role in susceptibility to RA may also influence the response to anti-TNF treatment.

We have previously investigated—and found no evidence for—an association of the two major RA susceptibility loci: *HLA-DRB1* shared epitope alleles and the *PTPN22* R620W polymorphism.<sup>5</sup> However, with the advent of genome-wide association (GWA) studies, there has recently been enormous progress in the identification of RA susceptibility genes. There are now at least 11 additional loci for which association with RA susceptibility has been confirmed in independent data sets, and the aim of the current study was to test the association of these markers with anti-TNF treatment response.



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://ard.bmj.com/info/unlocked.dtl>

## METHODS

## Markers

We selected a panel of single nucleotide polymorphism (SNP) markers mapping to 11 recently confirmed RA susceptibility loci for genotyping in a large cohort of patients treated with anti-TNF agents. These included two regions around the *TNFAIP3* locus on chromosome 6q23,<sup>7-9</sup> *STAT4* on chromosome 2q,<sup>7 10-12</sup> *TRAF1-C5* on chromosome 9,<sup>7 11 13</sup> a locus encompassing the *IL2* and *IL21* genes on chromosome 4q27,<sup>7 14 15</sup> *PRKCQ* on chromosome 10p15,<sup>7 16</sup> *KIF5A* on 12q13,<sup>7 16</sup> *CD40* on 20q13,<sup>7 13</sup> *CCL21* on 9p13,<sup>7</sup> *CTLA4* on chromosome 2q, *AFF3* also on chromosome 2q and *CD226* on 8q22.<sup>15 17</sup>

## Samples

The patient cohort consisted of patients with RA treated with anti-TNF drugs recruited from hospitals across the UK as part of the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS). These patients were originally recruited by the British Society for Rheumatology Biologics Register (BSRBR) and subsequently invited to participate in BRAGGSS, a study of genetic predictors of anti-TNF treatment. Inclusion criteria for enrolment in BRAGGSS were: (1) physician diagnosed RA; (2) the patient must be registered with the BSRBR, either starting or already receiving treatment with one of the three anti-TNF drugs etanercept, infliximab or adalimumab; and (3) the patient is of Caucasian origin, thus avoiding potential spurious associations arising as a result of population stratification. Patients were excluded from the study if they had missing 28 joint count disease activity score (DAS28) data at either baseline or at follow-up (6 months) or if they had stopped treatment due to adverse events during the follow-up period. The first cohort of BRAGGSS patients used here comprised 1092 patients, while associations were investigated further in an additional 338 patients. Clinical and demographic characteristics for both cohorts are shown in table 1.

## Genotyping

Genotyping was performed with 10 ng DNA using the Sequenom MassARRAY iPLEX system according to the manufacturer's instructions (<http://www.sequenom.com/>). Duplicate DNA samples were genotyped as part of quality control (QC) assessments.

## Analysis of data

Statistical analyses were performed in Stata Version 9.2 (StataCorp, College Station, Texas, USA) and in PLINK (<http://pnu.gmgh.harvard.edu/purcell/plink/>).<sup>18</sup> QC of DNA samples

and SNPs was performed by excluding those displaying <80% genotyping success. Multivariate linear regression analysis was used to assess the effect of each SNP genotype on response to treatment, using the continuous variable absolute change in DAS28 between baseline and 6-month follow-up as the outcome measure. Regression analyses were adjusted for confounding variables with a significant effect on anti-TNF treatment response: baseline DAS28, HAQ score, gender and concurrent DMARD therapy. Additive, genotypic, dominant and recessive models of inheritance were tested in Stata. *p* Values <0.05 were considered statistically significant and no corrections for multiple testing were performed. SNPs reaching statistical significance were genotyped in an additional cohort of patients with RA treated with anti-TNF drugs and the combined genotype data from the two cohorts were analysed. Possible differences in the effect of the associated variants on treatment response between the three anti-TNF drug types were investigated, both by drug type stratification and inclusion of an interaction term in the linear regression model.

## RESULTS

A total of 18 SNPs mapping to the 11 loci investigated were selected for genotyping (table 2). These were polymorphisms with previous evidence for association with RA susceptibility including some proxy SNPs in case of assay failure, selected using SNAP.<sup>19</sup>

The initial test cohort comprised 1092 samples; 80 samples were excluded by the <80% QC measure, leaving 1012 samples available for analysis. One SNP (rs13207033) in *TNFAIP3* was excluded from analysis due to <80% genotyping success rate, although a perfect proxy for this variant was successfully genotyped (rs13192841).

Two variants mapping to *AFF3* and one to the *CD226* locus demonstrated statistically significant evidence for association under an additive model (table 3) (*AFF3*: rs10865035, allele G coefficient -0.16 (95% CI -0.29 to -0.03), *p*=0.018; rs1160542, allele G coefficient 0.15 (95% CI 0.02 to 0.29), *p*=0.022; *CD226*: rs763361, allele C coefficient 0.16 (95% CI 0.03 to 0.29), *p*=0.016). rs1160542 served as a proxy (*r*<sup>2</sup>=0.97) for rs10865035, so these two associations represent a single effect at *AFF3*.

A SNP at the *STAT4* locus rs7574865 (along with the proxy SNP rs10181656) reached statistical significance under a dominant model but not in the genotypic or additive model (table 3). The association appears to be driven by the reduced response conferred by the heterozygous genotype, suggesting that this association may be a spurious finding.

In order to increase confidence in the association at these three loci, they were genotyped in an additional 338 anti-

**Table 1** Characteristics for first, additional and combined cohorts (1334 samples)

Characteristics	First cohort (n=1012)	Additional cohort (n=322)	Combined cohort (n=1334)
M:F, n (%)	229 (22.6):783 (77.4)	65 (20.2):257 (79.8)	294 (22.1):1038 (77.9)
Mean (SD) age at baseline (years)	56.5 (11.1)	56.7 (10.5)	56.6 (10.95)
Mean (SD) disease duration at baseline (years)	13.9 (9.8)	12.7 (10.2)	13.6 (9.89)
Mean (SD) HAQ score at baseline	2.05 (0.56)	1.9 (0.6)	2.0 (0.58)
Current smoker/ex-smoker/never smoked, n (%)	171 (16.9)/422 (41.7)/409 (40.4)	46 (14.3)/135 (41.9)/137 (42.6)	217 (16.3)/557 (41.8)/544 (40.8)
Receiving concurrent DMARD therapy, n (%)	720 (71.2)	249 (77.3)	968 (72.7)
Receiving concurrent steroid therapy, n (%)	414 (40.9)	127 (39.4)	541 (40.6)
Biologic naïve, n (%)	949 (93.8)	298 (92.6)	1246 (93.5)
Mean (SD) baseline DAS28	6.69 (0.98)	6.53 (0.98)	6.65 (0.98)
Mean (SD) change in DAS28 at 6-month follow-up	-2.47 (1.55)	-2.52 (1.40)	-2.48 (1.52)

DAS28, 28-joint count disease activity score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire.

**Table 2** Details of 18 confirmed RA susceptibility gene SNPs selected for genotyping

Gene	SNP	Chr	bp	Reason for selection
AFF3	rs10865035	2	100202166	Most associated T1D SNP associated with RA <sup>15</sup>
AFF3	rs1160542	2	100198587	rs10865035 proxy ( $r^2=0.967$ )
STAT4	rs7574865	2	191672878	Strongest association in US and UK studies <sup>10-12</sup>
STAT4	rs101816566	2	191678124	rs7574865 proxy ( $r^2=0.951$ )
CTLA4	rs231775	2	204440959	+49 exon 17 A→G SNP, implicated in autoimmunity <sup>15</sup>
CTLA4	rs3087243	2	204447164	Associated in US population <sup>7 15</sup>
IL2/IL21 locus	rs6822844	4	123728871	Most associated celiac disease SNP, associated with T1D and RA <sup>7 14 15</sup>
TNFAIP3	rs13207033	6	138007111	Most strongly associated SNP in US study <sup>9</sup>
TNFAIP3	rs13192841	6	138008907	rs13207033 proxy ( $r^2=1$ ); second US SNP <sup>9</sup>
TNFAIP3	rs6920220	6	138048197	Most strongly associated SNP in UK study <sup>8</sup>
TNFAIP3	rs5029937	6	138236844	Intron 2 SNP
CCL21	rs2812378	9	34700260	Most strongly associated SNP at locus <sup>7</sup>
TRAF1	rs10760130	9	122741811	Most strongly associated UK SNP <sup>11</sup>
TRAF1	rs2900180	9	122746203	Most strongly associated US SNP <sup>13</sup>
PRKCQ	rs4750316	10	6433266	Most associated SNP at locus <sup>16</sup>
KIF5A	rs1678542	12	56254982	Most strongly associated SNP at locus <sup>16</sup>
CD226	rs763361	18	65682622	Most associated T1D SNP, associated with MS, AITD and RA <sup>17</sup>
CD40	rs4810485	20	44181354	Most strongly associated SNP at locus <sup>7</sup>

AITD, autoimmune thyroid disease; bp, base pairs; Chr, chromosome; MS, multiple sclerosis; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism; T1D, type 1 diabetes.

TNF-treated RA samples which were reduced to 322 samples after the 80% QC measure. The clinical characteristics of this cohort are shown in table 1 and are similar to the initial cohort, allowing the data from both cohorts to be combined for analysis. The results of analysis of the additional samples alone are given in table S1 in the online supplement.

Power calculations performed in QUANTO computer program (2006) showed that, under an additive or a dominant model, the sample size in the combined cohort ( $n=1334$ ) provided >99% power to detect a difference in DAS28 score of  $\geq 0.6$  units (a clinically important change) at minor allele frequencies of  $\geq 0.05$ .

The SNPs mapping to *AFF3* and *CD226* remained statistically significantly associated with response under an additive model (*AFF3*: rs10865035, allele G coefficient  $-0.14$  (95% CI  $-0.25$  to  $-0.03$ ),  $p=0.015$ ; *CD226*: rs763361, allele C coefficient  $0.11$  (95% CI  $0.00$  to  $0.22$ ),  $p=0.048$ ) (table 4). However, the association at the *STAT4* locus continued to be driven by the heterozygous genotype in the combined data. Since this seems a biologically implausible model for association, we believe that the association at *STAT4* probably represents a false positive. In a separate analysis using the European League Against Rheumatism (EULAR) response criteria as the outcome measure, only rs10865035 in *AFF3* was associated, with good versus poor response (OR 1.46 (95% CI 1.13 to 1.88),  $p=0.0036$ ) (see table S2 in online supplement).

It is possible that polymorphisms may have different effects on the treatment response depending on which of the three anti-TNF drugs was used. Despite apparent drug-specific effects upon stratification by drug type, interaction

analysis revealed no statistically significant difference in treatment response between the three anti-TNF biological agents for either of the associated SNPs (additive model, *AFF3*: rs10865035,  $p=0.26$ ; *CD226*: rs763361,  $p=0.51$ ) (see table S3 in online supplement).

## DISCUSSION

This investigation of RA susceptibility loci in response to anti-TNF treatment is the largest study of genetic predictors of anti-TNF response performed to date. We have detected nominally significant effects at RA susceptibility variants mapping to the *AFF3* and *CD226* genes.

The identification of an effect on treatment response conferred by polymorphism within a susceptibility gene is not surprising as there are several examples in the literature where complex disease susceptibility genes encode therapeutic targets. For example, in T2D, the established susceptibility gene *PPARG* encodes a protein which is a target for the thiazolidinedione drugs.<sup>20</sup> In RA the drug abatacept, a CTLA4 analogue, was shown to be an effective therapy before the *CTLA4* gene was unequivocally demonstrated as associated with susceptibility to RA.<sup>7 15 21</sup> There are now examples of polymorphisms within susceptibility genes that influence response to treatment, such as variation in the T2D susceptibility gene *TCF7L2* which predicts response to sulfonylureas.<sup>6</sup>

However, the association of *CD226* and *AFF3* variants with the anti-TNF response is weak, and the addition of these markers into predictive models including clinical variables has only a modest effect, increasing the  $R^2$  value from 15.7% to 17.0%. This is in contrast to the large genetic effects seen in studies such as those of response to warfarin therapy. For example, genetic variants in the two genes *VKORC1* and *CYP2C9* account for about 40% of the variance in warfarin dose.<sup>22</sup> In that case the genes were originally targeted as candidates because they were known to lie on the warfarin metabolic pathway, and it may be argued that major genetic effects on the anti-TNF response might be expected to arise from variation within genes implicated in the TNF pathway. However, previous investigations by our group have failed to detect an association between a number of such genes and treatment response.<sup>23</sup> One notable exception is the association between the *TNF*  $-308$  SNP and the response to etanercept, but not infliximab.<sup>24</sup>

Even with the warfarin story, although major genetic effects have been identified, inclusion of these into models with clinical variables remains only moderately predictive of warfarin dose required or time to stabilise international normalised ratio.<sup>25</sup> A subsequent GWA study confirmed an association with *VKORC1* and *CYP2C9* loci and identified numerous signals which may represent other loci with smaller effects on warfarin requirements. Incorporation of these smaller effects may be required to develop accurate models of prediction.<sup>26</sup> Hence, the weak effects detected in the current study may yet prove to be clinically important when combined with other predictors of response to anti-TNF therapy.

In order to detect subtle effects, studies must be adequately powered. One of the most important strengths of this study is the large sample size employed; almost all similar investigations (with notable exceptions<sup>5 23 24</sup>) have focused on <500 patients with RA. The current sample size provided very high power (>99%) to detect a change in DAS28 of 0.6 units at minor allele frequency  $\geq 0.05$ . We are therefore confident in excluding modest effects at the variants that did not demonstrate evidence of association in our study.

**Table 3** DAS28 response data by genotype and association p values for 17 successfully genotyped SNPs in 1012 individuals

SNP	Gene	Chr	bp	Genotype	Count	Mean baseline DAS28	SD baseline DAS28	Mean change in DAS28	SD change in DAS28	HWE exact p value	First cohort (n=1012)			Additive model			Dominant model*		
											Genotypic global p value	Global p value	Coef	Min 95	Max 95	Global p value	Coef	Min 95	Max 95
rs10865035	AFF3	2	100202166	AA	240	6.72	1.02	-2.28	1.57	0.089	0.051	0.018	-0.16	-0.29	-0.03	0.024	-0.25	-0.46	-0.03
				AG	532	6.69	0.96	-2.51	1.51										
				GG	237	6.68	0.99	-2.58	1.63										
rs1160542	AFF3	2	100198587	AA	247	6.70	0.97	-2.59	1.61	0.050	0.066	0.022	0.15	0.02	0.29	0.101	0.17	-0.03	0.38
				AG	530	6.69	0.96	-2.49	1.51										
				GG	221	6.68	1.00	-2.25	1.56										
rs7574865	STAT4	2	191672878	GG	564	6.73	0.99	-2.57	1.55	0.400	0.051	0.094	0.13	-0.02	0.28	0.028	0.20	0.02	0.39
				GT	389	6.65	0.95	-2.33	1.58										
				TT	57	6.64	1.10	-2.49	1.40										
rs10181656	STAT4	2	191678124	CC	563	6.73	0.99	-2.57	1.54	0.559	0.067	0.122	0.12	-0.03	0.27	0.038	0.19	0.01	0.37
				CG	389	6.65	0.95	-2.33	1.60										
				GG	60	6.63	1.07	-2.50	1.37										
rs231775	CTLA4	2	204440959	AA	365	6.68	1.00	-2.50	1.53	0.794	0.775	0.500	0.04	-0.09	0.17	0.484	0.07	-0.12	0.25
				AG	482	6.69	0.98	-2.44	1.52										
				GG	165	6.73	0.94	-2.52	1.72										
rs3087243	CTLA4	2	204447164	GG	340	6.67	0.97	-2.53	1.64	0.948	0.712	0.570	0.04	-0.09	0.17	0.427	0.08	-0.11	0.27
				GA	492	6.74	0.96	-2.46	1.49										
				AA	176	6.61	1.05	-2.41	1.57										
rs6822844	IL2-IL21	4	123728871	GG	725	6.69	0.95	-2.45	1.58	0.151	0.376	0.317	-0.09	-0.26	0.08	0.208	-0.13	-0.33	0.07
				GT	254	6.68	1.05	-2.52	1.50										
				TT	31	7.00	0.84	-2.70	1.33										
rs13192841	TNFAIP3	6	138008907	GG	577	6.66	0.98	-2.50	1.59	0.672	0.406	0.469	0.05	-0.09	0.20	0.271	0.10	-0.08	0.28
				GA	371	6.72	0.99	-2.41	1.51										
				AA	64	6.77	0.92	-2.60	1.48										

**Table 3** Continued

Table 3 Continued

First cohort (n=1012)																			
SNP	Gene	Chr	bp	Genotype	Count	Mean baseline DAS28	SD baseline DAS28	Mean change in DAS28	SD change in DAS28	HWE exact p value	Genotypic global p value	Additive model			Dominant model*				
												Global p value	Coef	Min 95	Max 95	Global p value	Coef	Min 95	Max 95
rs6920220	TNFAIP3	6	138048197	GG	525	6.69	0.96	-2.49	1.49	0.430	0.536	0.314	0.07	-0.07	0.22	0.265	0.10	-0.08	0.28
				GA	413	6.69	1.00	-2.44	1.61										
				AA	71	6.68	1.02	-2.43	1.68										
rs5029937	TNFAIP3	6	138236844	GG	900	6.67	0.98	-2.44	1.54	0.763	0.463	0.216	-0.18	-0.47	0.11	0.227	-0.18	-0.48	0.11
				GT	105	6.91	0.92	-2.73	1.64										
				TT	2	7.46	0.35	-3.43	1.01										
rs2812378	CCL21	9	34700260	TT	379	6.67	1.02	-2.42	1.53	0.386	0.876	0.637	-0.03	-0.17	0.10	0.609	-0.05	-0.24	0.14
				TC	490	6.70	0.95	-2.51	1.56										
				CC	140	6.74	0.96	-2.48	1.62										
rs10760130	TRAF1	9	122741811	AA	313	6.71	0.99	-2.39	1.58	0.798	0.457	0.981	0.00	-0.13	0.13	0.520	-0.06	-0.26	0.13
				AG	492	6.68	0.94	-2.54	1.53										
				GG	200	6.71	1.07	-2.41	1.57										
rs2900180	TRAF1	9	122746203	CC	425	6.73	0.98	-2.47	1.61	0.077	0.730	0.592	0.04	-0.09	0.17	0.841	0.02	-0.16	0.20
				CT	441	6.65	0.95	-2.50	1.49										
				TT	146	6.70	1.05	-2.41	1.57										
rs4750316	PRKCC	10	6433266	GG	695	6.71	0.95	-2.54	1.56	0.510	0.346	0.387	0.07	-0.09	0.24	0.237	0.12	-0.08	0.31
				GC	283	6.67	1.01	-2.33	1.50										
				CC	33	6.43	1.23	-2.19	1.80										
rs1678542	KIF5A	12	56254982	CC	419	6.72	0.98	-2.50	1.55	0.448	0.724	0.600	0.04	-0.10	0.17	0.456	0.07	-0.11	0.25
				CG	473	6.65	0.96	-2.44	1.55										
				GG	119	6.74	1.05	-2.49	1.56										
rs763361	CD226	18	65682622	TT	272	6.65	1.00	-2.64	1.50	0.900	0.050	0.016	0.16	0.03	0.29	0.026	0.23	0.03	0.43
				TC	508	6.69	0.96	-2.45	1.57										
				CC	232	6.75	0.98	-2.32	1.57										
rs4810485	CD40	20	44181354	GG	607	6.68	0.95	-2.50	1.54	0.048	0.398	0.221	0.10	-0.06	0.27	0.325	0.09	-0.09	0.28
				GT	358	6.68	1.01	-2.40	1.56										
				TT	35	6.90	0.97	-2.46	1.65										

Significant p values (<0.05) are shown in bold type, italic indicates p<0.10

\*Results for the recessive model are not shown; only rs1160542 (AFF3) demonstrated association with treatment response under a recessive model (coef 0.23 (0.01, 0.45), p=0.037). bp, base pairs; Chr, chromosome; Coef, coefficient for minor allele; DAS, disease activity score; HWE, Hardy-Weinberg equilibrium; SNP, single nucleotide polymorphism.

**Table 4** DAS28 response data by genotype and association p values for three successfully genotyped SNPs in 1334 individuals

SNP	Gene	Chr	bp	Count	Mean baseline DAS28	SD baseline DAS28	Mean change in DAS28	SD change in DAS28	HWE exact p value	Genotypic global p value	Additive model			Dominant model				
											Genotype	Coef	Min 95	Max 95	Global p value	Coef	Min 95	Max 95
rs10865035	<i>AFF3</i>	2	100202166	320	6.66	1.01	-2.30	1.51	0.228	<b>0.036</b>	0.015	-0.14	-0.25	-0.03	<b>0.013</b>	-0.23	-0.41	-0.05
				688	6.65	0.97	-2.51	1.49										
				323	6.66	0.98	-2.59	1.57										
rs7574865	<i>STAT4</i>	2	191672878	738	6.69	0.97	-2.56	1.51	0.469	0.173	0.203	0.08	-0.04	0.21	0.097	0.13	-0.02	0.29
				514	6.64	0.98	-2.38	1.56										
				80	6.50	1.08	-2.42	1.36										
rs763361	<i>CD226</i>	18	65682622	359	6.62	1.01	-2.60	1.44	0.622	0.141	<b>0.048</b>	0.11	0.00	0.22	0.098	0.15	-0.03	0.32
				657	6.65	0.95	-2.48	1.56										
				318	6.69	1.03	-2.36	1.51										

Significant p values (<0.05) are shown in bold type, italic indicates p<0.10. bp, base pairs; Chr, chromosome; Coef, coefficient for minor allele (except at rs10865035); DAS, disease activity score; HWE, Hardy-Weinberg equilibrium; SNP, single nucleotide polymorphism.

The associated rs10865035 SNP maps to the 5' upstream region of *AFF3* located on chromosome 2q11. Interestingly, the SNP was associated not only with change in the DAS28 but also with EULAR response criteria; indeed, for the latter analysis, the association remained statistically significant even after applying a stringent Bonferroni correction ( $p_c=0.049$ ). The gene, also known as *AF4/FMR2*, is preferentially expressed on lymphoid cells and encodes a family of transcription factors that are thought to be implicated in the function of the lymphoid system.<sup>27</sup> We speculate that variation in *AFF3* may lead to an upregulated inflammatory response by lymphocytes, resulting in more circulating proinflammatory molecules and leading to a reduced response to TNF antagonists; further studies will be required to explore this.

The *CD226* gene maps to chromosome 18q22 and encodes a type I membrane protein molecule expressed on the surface of haematopoietic cells which is involved in the triggering of both T and NK cell cytotoxicity. The associated variant (rs763361) is a non-synonymous SNP encoding a glycine to serine substitution and carriage of the minor allele has previously been reported to be associated with RA susceptibility.<sup>17</sup> Alteration of T and NK cell cytotoxicity could once again lead to greater proinflammatory molecule production, thereby explaining why there is a reduced response to anti-TNF drugs.

A limitation of the current investigation is that no correction for multiple testing was applied and, if it was applied, the associations with change in DAS28 would not remain statistically significant (*AFF3*,  $p_c=0.195$ ; *CD226*,  $p_c=0.624$ ). It is therefore important that the findings of this study are validated in an independent cohort, but such validation was beyond the scope of the current study. Our strategy was to maximise sample size by genotyping all available DNA samples rather than splitting the cohort into test and confirmatory data sets. It is therefore possible that the associations may have arisen due to a type I error. However, our findings are in keeping with those in other complex diseases, in that susceptibility genes may also influence treatment response.<sup>6</sup>

In summary, we provide evidence for a weak association between SNPs in the *AFF3* and *CD226* RA susceptibility loci and response to anti-TNF treatment in patients with RA. The percentage of the variance explained by these genetic markers is only 1.3%. It is too early to say whether the response to anti-TNF treatment will be conferred through a number of genes, each with a small effect size, or whether genes exist that predict a large percentage of variance to treatment. Candidate gene studies have had limited success, however, in identifying predictors. We hypothesise that the response to treatment is polygenic and that well-powered GWA studies should be able to identify a genetic signature to identify those patients most—or, indeed, least—likely to benefit from these expensive but effective therapies.

**Acknowledgements** The authors thank the Arthritis Research Campaign for their support (arc grant reference no 17552). The authors are also grateful to the NIHR Manchester Biomedical Research Centre for support.

**Competing interests** None.

**Ethics approval** This study was approved by the South Manchester ethics committee (COREC 04/Q1403/37).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Patient consent** Obtained.

**REFERENCES**

1. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. *Rheumatology (Oxford)* 2002;**41**:793–800.
2. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in

- Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med* 2000;**343**:1594–602.
3. **Coenen MJ**, Toonen EJ, Scheffer H, *et al.* Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. *Pharmacogenomics* 2007;**8**:761–73.
  4. **Hyrich KL**, Watson KD, Silman AJ, *et al.* Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford)* 2006;**45**:1558–65.
  5. **Potter C**, Hyrich KL, Tracey A, *et al.* Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. *Ann Rheum Dis* 2009;**68**:69–74.
  6. **Pearson ER**, Donnelly LA, Kimber C, *et al.* Variation in TCF7L2 influences therapeutic response to sulfonyleureas: a GoDARTs study. *Diabetes* 2007;**56**:2178–82.
  7. **Raychaudhuri S**, Remmers EF, Lee AT, *et al.* Common variants at CD40 and other loci confer risk of rheumatoid arthritis. *Nat Genet* 2008;**40**:1216–23.
  8. **Thomson W**, Barton A, Ke X, *et al.* Rheumatoid arthritis association at 6q23. *Nat Genet* 2007;**39**:1431–3.
  9. **Plenge RM**, Cotsapas C, Davies L, *et al.* Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. *Nat Genet* 2007;**39**:1477–82.
  10. **Remmers EF**, Plenge RM, Lee AT, *et al.* STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N Engl J Med* 2007;**357**:977–86.
  11. **Barton A**, Thomson W, Ke X, *et al.* Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. *Hum Mol Genet* 2008;**17**:2274–9.
  12. **Lee HS**, Remmers EF, Le JM, *et al.* Association of STAT4 with rheumatoid arthritis in the Korean population. *Mol Med* 2007;**13**:455–60.
  13. **Plenge RM**, Seielstad M, Padyukov L, *et al.* TRAF1-C5 as a risk locus for rheumatoid arthritis – a genome-wide study. *N Engl J Med* 2007;**357**:1199–209.
  14. **Zhernakova A**, Alizadeh BZ, Bevova M, *et al.* Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. *Am J Hum Genet* 2007;**81**:1284–8.
  15. **Barton A**, Eyre S, Ke X, *et al.* Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. *Hum Mol Genet* 2009;**18**:2518–22.
  16. **Barton A**, Thomson W, Ke X, *et al.* Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. *Nat Genet* 2008;**40**:1156–9.
  17. **Hafler JP**, Maier LM, Cooper JD, *et al.* CD226 Gly307Ser association with multiple autoimmune diseases. *Genes Immun* 2009;**10**:5–10.
  18. **Purcell S**, Neale B, Todd-Brown K, *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;**81**:559–75.
  19. **Johnson AD**, Handsaker RE, Pulit SL, *et al.* SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics* 2008;**24**:2938–9.
  20. **Stumvoll M**, Häring H. Insulin resistance and insulin sensitizers. *Horm Res* 2001;**55**(Suppl 2):3–13.
  21. **Korhonen R**, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. *Basic Clin Pharmacol Toxicol* 2009;**104**:276–84.
  22. **Bodin L**, Verstuyft C, Tregouet DA, *et al.* Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. *Blood* 2005;**106**:135–40.
  23. **Bowes JD**, Potter C, Gibbons LJ, *et al.* Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. *Pharmacogenet Genomics* 2009;**19**:319–23.
  24. **Maxwell JR**, Potter C, Hyrich KL, *et al.* Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. *Hum Mol Genet* 2008;**17**:3532–8.
  25. **Klein TE**, Altman RB, Eriksson N, *et al.* Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med* 2009;**360**:753–64.
  26. **Cooper GM**, Johnson JA, Langae TY, *et al.* A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. *Blood* 2008;**112**:1022–7.
  27. **Ma C**, Staudt LM. LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. *Blood* 1996;**87**:734–45.

# Corrections

The department of one of the authors who co-authored all of the below papers has found that the affiliations were not correct. The correct affiliations for Professor P Emery, for all of the below articles, are: <sup>1</sup>Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds; <sup>2</sup>NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK.

1. **Keystone E**, Emery P, Peterfy CG, *et al*. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. *Ann Rheum Dis* 2009;**68**:216–21.
2. **Doward LC**, McKenna SP, Whalley D, *et al*. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. *Ann Rheum Dis* 2009;**68**:196–200.
3. **Potter C**, Hyrich KL, Tracey A, *et al*. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-TNF response in RA. *Ann Rheum Dis* 2009;**68**:69–74.
4. **Smolen JS**, Han C, van der Heijde DM, *et al*. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. *Ann Rheum Dis* 2009;**68**:823–7.
5. **Buch MH**, Boyle DL, Rosengren S, *et al*. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. *Ann Rheum Dis* 2009;**68**:1220–7.
6. **Emery P**, Van Vollenhoven R, Ostergaard M, *et al*. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. *Ann Rheum Dis* 2009;**68**:456–9.
7. **Bejarano V**, Conaghan PG, Proudman SM, *et al*. Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis. *Ann Rheum Dis* 2009;**68**:761–3.
8. **Rudwaleit M**, Landewé R, van der Heijde D, *et al*. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis* 2009;**68**:770–6.
9. **Bennett AN**, Marzo-Ortega H, Emery P, *et al*. Leeds Spondyloarthropathy Group. Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stage. *Ann Rheum Dis* 2009;**68**:765–7.
10. **Marzo-Ortega H**, McGonagle D, O'Connor P, *et al*. Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. *Ann Rheum Dis* 2009;**68**:1721–7.
11. **Gilworth G**, Emery P, Gossec L, *et al*. Adaptation and cross-cultural validation of the rheumatoid arthritis work instability scale (RA-WIS). *Ann Rheum Dis* 2009;**68**:1686–90.
12. **Gilworth G**, Emery P, Gossec L, *et al*. Adaptation and cross-cultural validation of the RA-WIS (Work Instability Scale). *Ann Rheum Dis* 2009;**68**:1686–90.
13. **Jarrett SJ**, Sivera F, Cawkwell LS, *et al*. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. *Ann Rheum Dis* 2009;**68**:1466–9.
14. **Haugeberg G**, Conaghan PG, Quinn M, *et al*. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Exploratory analysis from a 12-month randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2009;**68**:1898–901.
15. **Genovese MC**, Breedveld FC, Emery P, *et al*. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. *Ann Rheum Dis* 2009;**68**:1894–7.
16. **Kekow J**, Moots RJ, Emery P, *et al*. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. *Ann Rheum Dis* 2010;**69**:222–5.
17. **Furst DE**, Keystone EC, Fleischmann R, *et al*. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. *Ann Rheum Dis* 2010;**69**(Suppl 1):i2–29.
18. **Freeston JE**, Wakefield RJ, Conaghan PG, *et al*. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. *Ann Rheum Dis* 2010;**69**:417–9.
19. **Jones E**, Churchman SM, English A, *et al*. Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level. *Ann Rheum Dis* 2010;**69**:450–7.
20. **Alten RE**, Zerbini C, Jeka S, *et al*. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. *Ann Rheum Dis* 2010;**69**:364–7.
21. **Machold KP**, Landewé R, Smolen JS, *et al*. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. *Ann Rheum Dis* 2010;**69**:495–502.
22. **Schoels M**, Knevel R, Aletaha D, *et al*. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. *Ann Rheum Dis* 2010;**69**:638–43.
23. **Smolen JS**, Aletaha D, Bijlsma JW, *et al*. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis* 2010;**69**:631–7.
24. **Burr ML**, Naseem H, Hinks A, *et al*. BIRAC Consortium; YEAR Consortium. PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. *Ann Rheum Dis* 2010;**69**:666–70.
25. **Emery P**, Durez P, Dougados M, *et al*. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). *Ann Rheum Dis* 2010;**69**:510–16.
26. **Bennett AN**, Rehman A, Hensor EM, *et al*. The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. *Ann Rheum Dis* 2010;**69**:891–4.
27. **Nam JL**, Winthrop KL, van Vollenhoven RF, *et al*. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. *Ann Rheum Dis* 2010;**69**:976–86.
28. **Smolen JS**, Landewé R, Breedveld FC, *et al*. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2010;**69**:964–75.
29. **Tan RJ**, Gibbons LJ, Potter C, *et al*. BRAGGSS. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. *Ann Rheum Dis* 2010;**69**:1029–35.
30. **Robinson JI**, Barrett JH, Taylor JC, *et al*. YEAR Consortium; BRAGGSS. Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. *Ann Rheum Dis* 2010;**69**:1054–7.
31. **Cohen SB**, Keystone E, Genovese MC, *et al*. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. *Ann Rheum Dis* 2010;**69**:1158–61.
32. **Haugeberg G**, Bennett AN, McGonagle D, *et al*. Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational study. *Ann Rheum Dis* 2010;**69**:1364–6.
33. **Schoels M**, Aletaha D, Smolen JS, *et al*. Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. *Ann Rheum Dis* 2010;**69**:575–8.
34. **Eyre S**, Flynn E, Martin P, *et al*. No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. *Ann Rheum Dis* 2010;**69**:1407–8.
35. **Eyre S**, Hinks A, Flynn E, *et al*. Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. *Ann Rheum Dis* 2010;**69**:1572–3.
36. **Orozco G**, Eyre S, Hinks A, *et al*. Wellcome Trust Case Control consortium YEAR Consortium. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. *Ann Rheum Dis* 2010;**69**:813–16.
37. **Emery P**, Durez P, Dougados M, *et al*. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). *Ann Rheum Dis* 2010;**69**:510–16.
38. **Saleem B**, Keen H, Goeb V, *et al*. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? *Ann Rheum Dis* 2010;**69**:1636–42.
39. **Barkham N**, Coates LC, Keen H, *et al*. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. *Ann Rheum Dis* 2010;**69**:1926–8.
40. **Emery P**, Deodhar A, Rigby WF, *et al*. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). *Ann Rheum Dis* 2010;**69**:1629–35.
41. **Dixon WG**, Hyrich KL, Watson KD, *et al*. BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2010;**69**:1086–91.